Daniel L. Riggs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel L. Riggs has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Gabriel Barwick
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
74 shared publications - Caleb K. Stein
Mayo Clinic 3 Division of Hematology and Oncology Scottsdale, Arizona
74 shared publications - Lawrence H. Boise
Emory University
74 shared publications - Nizar Jacques Bahlis
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
74 shared publications - Paola Neri
University of Calgary
74 shared publications - Peter Leif Bergsagel
Mayo Clinic Arizona
74 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Differentially expressed genes and GSEA in OPM2 cells following shRNA knockdown of IKZF3.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Univariate and multi-variate analysis of ETV4 expression in the CoMMpass NDMM patients treated with IMiD as part of front-line therapy (N=567).
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 ChIP-seq binding sites in RPMI8226 cells.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
JASPAR transcription factor binding motifs enriched in IKZF1-bound regions in RPMI8226 cells where the cognate transcription factor was expressed at greater than 1 FPKM and the FDR enrichment significance P ≤ 10e-10.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
ETV4 mRNA data and outcome from the POLLUX and MM-010 trials.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples